Gene: PCLO

27445
ACZ|PCH3
piccolo presynaptic cytomatrix protein
protein-coding
7q21.11
Ensembl:ENSG00000186472 MIM:604918 Vega:OTTHUMG00000154853 UniprotKB:Q9Y6V0
NG_047145.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.993e-1 (AD)  1.672e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
NBEA0.959
SLC8A10.956
SYNJ10.954
GPR1580.953
RYR20.951
DMXL20.949
NRXN30.947
AAK10.946
ERC20.946
WDR70.944

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RAB13-0.586
CSAG1-0.577
COPZ2-0.563
HEY2-0.554
RNF135-0.554
ROM1-0.538
ASB4-0.536
RHOD-0.536
YES1-0.535
FLT3LG-0.535

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C02017516 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione"16 alpha-ethyl-21-hydroxy-19-nor-4-pregnene-3,20-dione results in increased expression of PCLO mRNA"20519331
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of PCLO mRNA"21394737
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCLO mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCLO mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCLO mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCLO mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of PCLO gene27153756
C103303alitretinoinalitretinoin results in decreased expression of PCLO mRNA28689802
D001151ArsenicArsenic affects the methylation of PCLO gene25304211
D001280AtrazineAtrazine results in decreased expression of PCLO mRNA25929836
C030935benz(a)anthracenebenz(a)anthracene results in increased expression of PCLO mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of PCLO mRNA26001963
C006780bisphenol Abisphenol A results in decreased expression of PCLO mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of PCLO gene28505145
D002220CarbamazepineCarbamazepine affects the expression of PCLO mRNA25979313
D004390ChlorpyrifosChlorpyrifos results in decreased expression of PCLO mRNA18668222
D003300CopperCopper deficiency results in increased expression of PCLO mRNA26033743
D016572CyclosporineCyclosporine results in decreased expression of PCLO mRNA20106945
D019833GenisteinGenistein results in decreased methylation of PCLO gene28505145
D017313FenretinideFenretinide results in decreased expression of PCLO mRNA28973697
D007052IbuprofenIbuprofen results in increased expression of PCLO mRNA25596134
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of PCLO mRNA26752646
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of PCLO mRNA23179753
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of PCLO mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of PCLO mRNA"25554681
D009532NickelNickel results in decreased expression of PCLO mRNA24768652|2558310
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PCLO mRNA27935865
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCLO mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of PCLO mRNA26272509
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of PCLO mRNA27935865
C502851quinocetonequinocetone results in increased expression of PCLO mRNA27046791
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of PCLO mRNA25895662
D012906SmokeSmoke results in decreased expression of PCLO mRNA21095227
C017947sodium arsenitesodium arsenite results in increased expression of PCLO mRNA22714537
D053260SootSoot results in decreased expression of PCLO mRNA26551751
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PCLO mRNA24680724
D013849ThimerosalThimerosal results in increased expression of PCLO mRNA27188386
D014028Tobacco Smoke PollutionTobacco Smoke Pollution affects the expression of PCLO mRNA20133372
D014050TolueneToluene results in increased expression of PCLO mRNA22967744
C012589trichostatin Atrichostatin A results in increased expression of PCLO mRNA24935251
D014520UrethaneUrethane results in increased expression of PCLO mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCLO mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of PCLO mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of PCLO mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions affects the methylation of PCLO gene25560391
C029297vinylidene chloridevinylidene chloride results in decreased expression of PCLO mRNA26682919

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005509calcium ion binding-ISS-  
GO:0005522profilin binding-ISS-  
GO:0005544calcium-dependent phospholipid binding-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007010cytoskeleton organization-ISS-  
GO:0007416synapse assembly-IEA-  
GO:0016079synaptic vesicle exocytosis-NAS10508862  
GO:0017157regulation of exocytosis-IEA-  
GO:0019933cAMP-mediated signaling-IEA-  
GO:0030073insulin secretion-IEA-  
GO:0035418protein localization to synapse-IEA-  
GO:0099526presynapse to nucleus signaling pathway-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005856cytoskeleton-NAS10508862  
GO:0014069postsynaptic density-IEA-  
GO:0030054cell junction-IEA-  
GO:0045202synapse-ISS-  
GO:0048788cytoskeleton of presynaptic active zone-TAS15217342  
GO:0070062extracellular exosome-HDA18570454  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29779672Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial. (2018 May 17)Gelfond JUrol Oncol